CA-SOLIDIGM
6.8.2024 17:22:27 CEST | Business Wire | Press release
Today, Solidigm, a leading provider of innovative NAND flash memory solutions, announced the launch of the SolidigmTM D7-PS1010 and D7-PS1030 data center solid-state drives (SSDs). As the fastest PCIe 5.0 SSDs1 shipping in volume today, these drives are well suited for the IO intensity found in modern mainstream, mixed, and write-centric workloads.
“The Solidigm D7-PS1010 and D7-PS1030 SSDs were meticulously engineered to meet the increasingly demanding IO requirements across a range of workloads such as general-purpose servers, OLTP, server-based storage, decision support systems and AI/ML,” said Greg Matson, Senior Vice President of Strategic Planning and Marketing at Solidigm. “In a world where every watt counts, these drives are PCIe 5.0 done right, not only delivering industry-leading four-corner performance,2 but also up to 70% better energy efficiency compared to similar drives by other manufacturers.3”
Available in E3.S and U.2 form factors, the newest Solidigm SSDs come in a range of capacities and endurance options and are a strong extension to the company’s portfolio of best-in-industry storage for AI.
D7-PS1010
A standard endurance (SE) drive, the Solidigm D7-PS1010 is available in 1.92TB, 3.84TB, 7.68TB, and 15.36TB capacities. Over a 5-year period, the SE models provide 1.0 drive writes per day (DWPD) and boast substantial maximum lifetime program/erase cycles, with 28 petabytes written (PBW) for the 15.36TB variant. In server-based storage solutions, the D7-PS1010 can accelerate sequential write throughput up to 37 percent faster than drives with similar specifications.4 Offering a balance of performance and capacity, this drive is ideal for a wide range of mainstream applications.
D7-PS1030
A mid-endurance (ME) drive, the Solidigm D7-PS1030 is available in 1.6TB, 3.2TB, 6.4TB, and 12.8TB capacities and offers an impressive 70 PBW for the 12.8TB variant. When placed in an all-flash performance tier for AI workloads, the D7-PS1030 helps overcome hard disk drive (HDD) performance, endurance, and reliability limitations. With write performance more than double that of the previous generation Solidigm drive,5 the D7-PS1030 is particularly suited for operations requiring write-intensive usages such as caching and checkpointing.
The new drives are built to excel at every stage of the AI data pipeline and deliver up to 50 percent higher throughput in certain pipeline phases6 compared to similar drives in their class. These SSDs can be deployed as GPU direct attach drives in GPU servers or as part of a high-performance all-flash tier supporting lower-performing HDDs in network attach storage configurations.
“As AI workloads continue to surge, storage performance becomes critical,” said Ace Stryker, Director of Market Development at Solidigm. “The Solidigm D7-PS1010 and D7-PS1030 are a game-changer for AI-driven enterprises, capable of outperforming competitors at critical stages of the AI pipeline.”
With this launch, Solidigm continues its commitment to delivering industry-leading quality and reliability. By employing methodologies like testing to zero tolerance for data errors,7 built-in redundancies, enhanced power loss management, and engineering for performance consistency over the life of the drive,8 these SSDs far surpass required industry specifications and common practices. Combined with new OCP-compliant thermal management capabilities, and new security capabilities such as secure boot and data at rest protection and attestation, the D7-PS1010 and D7-PS1030 drives are designed to be deployed with utmost confidence in cloud and enterprise usages.
For more information on how Solidigm D7-PS1010 and Solidigm D7-PS1030 drives can help you power your workloads, visit our website.
About Solidigm
Solidigm is a leading global provider of innovative NAND flash memory solutions. Solidigm technology unlocks data’s unlimited potential for customers, enabling them to fuel human advancement. Originating from the sale of Intel’s NAND and SSD business, Solidigm became a standalone U.S. subsidiary of semiconductor leader SK hynix in December 2021. Headquartered in Rancho Cordova, California, Solidigm is powered by the inventiveness of team members in 13 locations around the world. For more information, please visit solidigm.com and follow us on Twitter and on LinkedIn. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. (d/b/a Solidigm).
______________________
1 Comparing product specifications and measured real-life workload performance across widely shipping PCIe 5.0 data center SSDs at the industry’s highest volume capacity point of 3.84TB (using Solidigm 2023 and 2024 shipments as industry representative data).
2 Four-corner comparison data is based on publicly available information from Samsung, Kioxia, and Micron.
3 Comparing 7.68TB, Samsung PM1743 and Solidigm D7-PS1010. Power is measured using Quarch Technology. Solidigm D7-PS1010 (128KB SW QD128 IOPS/Watt 3,874), Samsung PM1743 (128KB SW QD128 IOPS/Watt 2,272).
4 Workload IO characteristics based on research of publicly available materials conducted by Solidigm. Comparing SolidigmTM D7-PS1010 3.84TB (128KB Seq Write QD128 8.2 MB/s) vs Samsung PM1743 3.84TB (128KB Seq Write QD128 6.0 MB/s).
5 As compared to previous generation Solidigm™ D7-P5520 and D7-P5620.
6 Workload IO characteristics based on research of publicly available materials conducted by Solidigm. SolidigmTM D7-PS1010 7.68TB (32KB SW QD32 9.03GB/s 113us) vs Samsung PM1743 7.68TB (32K SW QD32 6.03GB/s 170us).
7 Solidigm drives are tested to 1E-18 under full range of conditions and cycle counts throughout the life of the drive which is 100X higher than 1E-16 specified in JEDEC – Solid State Drive Requirements and Endurance Test Method (JESD218). https://www.jedec.org/standards-documents/focus/flash/solid-state-drives.
8 Refer to SolidigmTM D7-PS1010 product specifications for IOPS consistency. Solidigm expects up to 5% variation in throughput between drive-to-drive runs. IOPS variability measured after adjusting SSD cycle limit to simulate end of life behavior. Results are estimated or simulated. Actual results may vary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806563458/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
